Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia.

Autor: Nolan BJ; Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Equinox Gender Diverse Clinic, Thorne Harbour Health, Melbourne, Victoria, Australia., Cheung AS; Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Internal medicine journal [Intern Med J] 2024 Sep; Vol. 54 (9), pp. 1450-1457. Date of Electronic Publication: 2024 Jul 26.
DOI: 10.1111/imj.16413
Abstrakt: Gender-affirming hormone therapy (GAHT) is used by many transgender and gender-diverse adults to align physical characteristics with their gender identity, reduce gender incongruence and improve psychological functioning. This narrative review provides an overview of the initiation and monitoring of GAHT in an Australian context. Trans individuals treated with testosterone typically receive standard testosterone doses and formulations recommended for cisgender men, whereas those receiving estradiol GAHT are typically treated with estradiol in combination with an anti-androgen in those without orchidectomy. Proactive monitoring and mitigation of cardiovascular risk factors is pertinent in all transgender and gender-diverse adults and bone health is an important consideration in those using estradiol GAHT.
(© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.)
Databáze: MEDLINE
Externí odkaz: